Standard BioTools
LAB
100 hedge funds and large institutions have $941M invested in Standard BioTools in 2013 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
85% more capital invested
Capital invested by funds: $509M → $941M (+$431M)
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
32% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $7.66M
16% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 32
12% more funds holding
Funds holding: 89 → 100 (+11)
Top Buyers
Top Sellers
| 1 |
Jennison Associates
New York
|
-$20M |
| 2 |
Primecap Management
Pasadena,
California
|
-$8.35M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$7M |
| 4 |
VAM
Visium Asset Management
New York
|
-$6.62M |
| 5 |
JP Morgan Chase
New York
|
-$6.36M |
LAB Hedge Fund Activity: Q4 2013 in Review
100 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2013, worth a combined $941M — up 85% from $509M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LAB positions and 14 closed out — a net gain of 11 holders — while 37 added to existing stakes and 32 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $22M. The largest seller was Jennison Associates, cutting an estimated $20M.
- 100 institutional investors held Standard BioTools (LAB) as of Q4 2013, up from 89 in Q3 2013.
- Funds reported $941M of Standard BioTools stock for Q4 2013, up 85% quarter-over-quarter.
- 25 funds opened new Standard BioTools positions in Q4 2013 and 14 closed out, a net change of +11 holders.
- The largest Standard BioTools buyer in Q4 2013 was Lord, Abbett & Co, an estimated $22M added.
- The largest Standard BioTools seller in Q4 2013 was Jennison Associates, an estimated $20M sold.
Based on aggregated 13F filings for Q4 2013.